Hypercholesterolemia Accelerates the Initiation and Progression of Angiotensin II-induced Abdominal Aortic Aneurysms

Jing Liu[1], Hisashi Sawada[2], Deborah A. Howatt[2], Jessica J. Moorleghen[2], Olga A. Vsevolozhskaya[3], Alan Daugherty[1,2,4], Hong S. Lu[1,2,4]

[1] Department of Pharmacology and Nutritional Sciences
[2] Saha Cardiovascular Research Center
[3] Department of Biostatistics
[4] Department of Physiology,
University of Kentucky, Lexington, KY

Running title: Hypercholesterolemia in AngII-induced AAAs

Corresponding Author:
Hong Lu
Saha Cardiovascular Research Center
BBSRB Room B249
741 South Limestone
Lexington, KY 40503-0509
Telephone : (859)323-4639
E-mail : Hong.Lu@uky.edu

ABSTRACT

Objective: This study determined whether hypercholesterolemia contributes to the initiation and progression of angiotensin (Ang)II-induced abdominal aortic aneurysms (AAAs) in mice.

Methods and Results: To determine whether hypercholesterolemia accelerates the initiation of AAAs, male low-density lipoprotein (LDL) receptor -/- mice were either fed one week of Western diet prior to starting AngII infusion or started Western diet one week after the initiation of AngII infusion. During the first week of AngII infusion, mice fed normal diet had less luminal expansion of the suprarenal aorta compared to those started Western diet after the first week of AngII infusion. The two groups achieved comparable luminal dilation on week 2 through week 6 of AngII infusion as monitored by ultrasound. To determine whether hypercholesterolemia contributed to the progression of AAAs, male LDL receptor -/- mice were fed Western diet and infused with AngII for 4 weeks. Mice with established AAAs were then stratified into two groups

based on luminal diameters measured by ultrasound. Mice in one group were continuously fed Western diet, and diet in the other group was switched to normal diet. AngII infusion was continued for another 8 weeks in both groups. Plasma cholesterol concentrations were rapidly reduced to approximately 500 mg/dl within one week of normal diet feeding in mice switched to normal diet. Luminal expansion progressed constantly in mice continuously fed Western diet, whereas no continuous expansion was detected in mice that were switched to normal diet.

Conclusions: Hypercholesterolemia accelerates both the initiation and progression of AngII-induced AAAs.

Clinical Relevance: There are reports on the contribution of hypercholesterolemia to AAAs in clinical observational or retrospective studies. However, it is not feasible to study whether hypercholesterolemia contributes to the initiation or progression of AAAs in human. This study using AngII-induced AAA mouse model provides solid evidence that hypercholesterolemia contributes to both the initiation and progression of AAAs, supporting that statin therapy at any stage of AAA development may be beneficial to patients with AAAs.

Keywords: abdominal aortic aneurysms, angiotensin, plasma cholesterol, hypercholesterolemia, LDL receptor

INTRODUCTION

Hypercholesterolemia augments the development of angiotensin II (AngII)-induced abdominal aortic aneurysms (AAAs) in male mice.[1-6] As a standard protocol, male low-density lipoprotein (LDL) receptor -/- mice are fed a Western diet one week prior to starting AngII infusion.[7] This one week of Western diet feeding leads to profound increases of plasma cholesterol concentrations to more than 1,000 mg/dl.[3] It is unclear whether a pre-existing hypercholesterolemic status is important to the initiation of AngII-induced AAAs, or it is critical for the progression of AngII-induced AAAs.

Plasma total cholesterol concentrations are below 300 mg/dl in LDL receptor -/- mice fed normal diet, but increase to more than 1000 mg/dl within a week of Western diet feeding.[3,8-10] This mouse strain with diet manipulation provides an optimal model to determine whether hypercholesterolemia contributes to the initiation and progression of AngII-induced AAAs. In this study using LDL receptor -/- mice, we determined whether hypercholesterolemia promote the initiation of AngII-induced AAAs, and whether maintaining hypercholesterolemic condition be important for the progression of AAAs.

METHODS

The raw data that support the findings reported in this manuscript are available

from the corresponding author upon reasonable request.

Mice and Diet

Male low-density lipoprotein (LDL) receptor -/- mice (8 weeks old) were purchased from The Jackson Laboratory (Stock # 2207; Bar Harbor, ME, USA). Mice were housed in individually vented cages (5 mice/cage) on a light:dark cycle of 14:10 hours. The cage bedding was Teklad Sani-Chip bedding (Cat # 7090A; Envigo, Madison, WI, USA). Mice were fed a normal rodent laboratory diet (Diet # 2918; Envigo) and given drinking water from a reverse osmosis system ad libitum. To induce hypercholesterolemia, mice were fed a Western diet supplemented with saturated fat extracted from milk (21% wt/wt) and cholesterol (0.15% wt/wt supplemented and 0.05% wt/wt from the fat source; Diet # TD.88137; Envigo). Mice died of any reason prior to termination were excluded for data analysis.

In this study, we only used male mice because female LDL receptor -/- mice have very low incidence of AngII-induced AAAs.[3,11,12] All mouse experiments reported in this manuscript were performed with the approval of the University of Kentucky Institutional Animal Care and Use Committee (University of Kentucky IACUC protocol number: 2006-0009).

Mini Osmotic Pump Implantation and Angiotensin II Infusion

To induce AAAs, mice were infused with 1 μg/kg/min of AngII (Cat # H-1705; Bachem, Torrance, CA, USA) subcutaneously via Alzet mini osmotic pumps (Alzet Model # 2006; Durect Corp, Cupertino, CA, USA).[7] In the first study (Figure 1A), one group of mice started Western diet one week prior to AngII infusion (WD group), whereas the other group started this Western diet one week after initiating AngII infusion (ND - WD group). AngII infusion duration was 6 weeks for both groups.

In the second study (Figure 2A), all mice were fed Western diet for one week prior to AngII infusion. Lumen diameters of suprarenal aortas were measured using noninvasive high frequency ultrasound system (Vevo 2100 with MS550D; FUJIFILM VisualSonics, Toronto, ON, Canada) at baseline and on day 28 of AngII infusion. AAAs were defined as 50% or more increase of the maximal lumen diameter of the suprarenal aorta on day 28 compared to the baseline (day 0). Based on luminal diameter measurements, mice exhibiting AAAs were stratified into two groups, and then either continuously fed Western diet (WD group) or switched to normal diet (Group 2: WD - ND). These two groups were infused with AngII for an additional 8 weeks. AngII infusion duration was 12 weeks achieved by implanting two mini osmotic pumps separately (Alzet Model # 2006): First pump was implanted on day 0 and replaced by the second pump on day 43. The second pump was preincubated in saline at 37 °C for more than 60 hours to permit immediate delivery of AngII that continued for another 6 weeks.

Ultrasonography

Luminal diameters of suprarenal aortas were measured using Vevo 2100 ultrasound imaging system at indicated time points.[13] Mice were anesthetized with

isoflurane and restrained in a supine position. Short-axis scan was performed from the level of left renal artery moving vertically up to the suprarenal region. One hundred frames of cine loops were acquired and the maximal lumen diameter of the suprarenal aortic region was measured on images during aortic dilation phase. Luminal diameters were measured by one investigator, and verified by another investigator independently who were blind to study groups.

Plasma Cholesterol Measurements

During each study, mice were bled consciously with submandibular bleeding. At termination mice were anesthetized using ketamine/xylazine cocktail, and blood samples were harvested by right ventricular puncture. All blood samples were collected with EDTA (final concentration: 1.8 mg/ml) and centrifuged at 400 g for 20 minutes, 4 °C to prepare plasma. Plasma cholesterol concentrations were measured using an enzymatic kit (Cat # 439-17501; Wako Chemicals USA, Richmond, VA, USA).

Quantification of Aortic Dilation and Atherosclerosis

Aortas were dissected, fixed, cleaned, and pinned. Maximal outer diameter of the suprarenal aorta was measured ex vivo as a parameter for aortic dilation using Image-Pro software (Version 7; Media Cybernetics, Bethesda, MD, USA).

Thoracic aortas were cut open and pinned for quantification of intimal area and atherosclerotic lesion area in the ascending aorta, aortic arch and 3 mm of the descending aorta using an en face technique.[14,15] Atherosclerotic lesions, calculated as percent lesion area (lesion area/intimal area x 100%), were compared between groups following the recommendations of the AHA statement.[16]

Statistical Analyses

Data are represented as means ± standard errors of means (SEM). To compare two groups on a continuous variable after termination, unpaired two-sided Student's t test was performed for normally distributed and equally variant values, and Mann-Whitney rank sum test was used for variables not passing normality or equal variance test. Plasma cholesterol concentrations and luminal diameters of suprarenal aortas measured by ultrasonography at a series of time points were analyzed using linear mixed-effects models to compare trends over time among the sub-groups within the cohort, with random effects accounting for within-animal correlation. In general, unstructured correlation matrix with unequal variances was assumed to account for dependence among observations over time and within mice. Models were built using R version 3.3.2 statistical software. $P < 0.05$ was considered statistically significant.

RESULTS

Hypercholesterolemia accelerated the initiation of AngII-induced AAAs

Mice (N = 10/group) were randomized into two groups: WD group started Western diet one week prior to AngII infusion, and ND - WD group started this diet one week after AngII infusion was initiated (Figure 1A). Three mice in WD group were

excluded for data analysis due to aortic rupture. Plasma cholesterol concentrations rapidly increased to approximately 1000 mg/dl prior to the start of AngII infusion in WD group, whereas plasma cholesterol concentrations remained significantly lower within the first two weeks of AngII infusion in ND - WD group (Figure 1B). During the first week of AngII infusion, maximal luminal diameters of suprarenal aortas were smaller in ND - WD group than in WD Group as determined by ultrasonography (P = 0.0004). Luminal diameters became comparable between the two groups on 2 - 6 weeks of AngII infusion (Figure 1C), as were also validated by ex vivo measurements after termination (Figure 1D). Consistent with the less duration of hypercholesterolemia, atherosclerotic lesions were smaller in ND - WD group than in WD group (Figure 1E).



Figure 1

Hypercholesterolemia accelerated the initiation of AngII-induced AAAs in male LDL receptor -/- mice. (A) Mice in WD group started Western diet feeding one week prior to AngII infusion, and mice in ND - WD group started Western diet one week after the initiation of AngII infusion. AngII infusion duration was 6 weeks. (**B**) Plasma cholesterol concentrations were measured using an enzymatic method. * P < 0.001, = 0.007, and < 0.001 between the two groups on Week 0, 1, and 2, respectively. (**C**) Maximal luminal diameters of suprarenal aortas were measured using ultrasound.* P = 0.004 on week 1. The orange arrow in (**B**) and (**C**) indicates the start of Western diet feeding. (**D**) Maximal outer diameters of suprarenal aortas were measured using an ex vivo method. (**E**) Atherosclerosis was measured by an en face method. * P = 0.008. Triangles are values from individual mice. Circles represent means and error bars represent SEM.

Hypercholesterolemia augmented the progression of AngII-induced AAAs

Seventy-nine male LDL receptor -/- mice were fed Western diet for one week prior to AngII infusion. The interval of AngII infusion was 4 weeks when Western diet continued. Eight mice died of aortic rupture during the 4 weeks of AngII infusion. Four weeks after AngII infusion 33 mice of the remaining 71 mice were stratified into two groups based on maximal luminal diameters (≥ 50% than baseline) of suprarenal aortas measured by ultrasound. Mice in WD group were fed Western diet continuously and diet for WD - ND group was changed to normal diet (Figure 2A). AngII infusion continued for another 8 weeks among these 33 mice. Two mice were excluded for data analysis due to abdominal aortic rupture. Therefore, 16 mice in WD group and 15 mice

in WD - ND group were included for data analysis. Plasma cholesterol concentrations decreased rapidly in WD - ND group within one week after diet change and remained low during the rest interval of AngII infusion (Figure 2B). Maximal luminal diameters of suprarenal aortas continuously increased in mice fed Western diet, but kept constant during the rest 8 weeks of AngII infusion in mice fed normal diet (Figure 2C). This significant effect of aortic diameters detected using ultrasound was confirmed after termination by ex vivo measurements (Figure 2D). Consistent with attenuation of hypercholesterolemia, atherosclerotic lesion sizes were smaller in WD - ND group than in WD group (Figure 2E).



Figure 2

Hypercholesterolemia contributed to the progression of AngII-induced AAAs in male LDL receptor -/- mice. (A) Mice in both groups started Western diet feeding one week prior to AngII infusion. Mice in WD group had been fed Western diet during AngII infusion, and diet for mice in WD - ND group was changed to normal diet after 4 weeks of AngII infusion. AngII infusion duration for both groups was 12 weeks. (**B**) Plasma cholesterol concentrations were measured using an enzymatic method. * $P < 0.001$ on week 5, 6, ans 12. (**C**) Maximal luminal diameters of suprarenal aortas were measured with ultrasound. * $P = 0.02$ and <0.001 on week 6 and 12, respectively. The orange arrow in (**B**) and (**C**) indicates diet was switched from Western diet to normal diet. (**D**) Maximal outer diameters of suprarenal aortas were measured using an ex vivo method. * $P < 0.001$. (**E**) Atherosclerosis was measured by an en face method. * $P < 0.001$. Triangles are values from individual mice. Circles represent means and error bars represent SEM.

DISCUSSION

This study has demonstrated that hypercholesterolemia accelerates the initiation and augments the progression of AngII-induced AAAs. This was accomplished using adult male LDL receptor -/- mice fed Western diet that can rapidly change plasma cholesterol concentrations.[3] This study has not only confirmed previous reports that Western diet feeding rapidly increases plasma cholesterol concentrations,[3,8,10] but also has provided evidence that plasma cholesterol concentrations reduce promptly after Western diet has been withdrawn in LDL receptor -/- mice.

In this study, we used atherosclerosis as a "positive" control when we compared abdominal aortic dilation between groups because atherosclerosis has positive association with the magnitude and duration of hypercholesterolemia.[3,16,17] Mice with either delayed Western diet feeding or removal of Western diet had less atherosclerotic lesions, which were consistent with lower plasma cholesterol concentrations or shorter period of hypercholesterolemia. In contrast, magnitude of hypercholesterolemia did not affect the development of AngII-induced AAAs, but removal of hypercholesterolemic status attenuated the progression of AngII-induced AAAs. These results support our previous findings that hypercholesterolemia augmenting AngII-induced AAAs has a threshold effect independent of the absolute concentration of plasma total cholesterol.[3] In addition, the present study provides evidence that hypercholesterolemia accelerates AngII-induced AAAs during both the initiative and the progressive stages. These findings support that inhibition of hypercholesterolemia is critical to prevent and attenuate the development of AAAs.

Many researchers use apolipoprotein E deficient (*Apoe*$^{-/-}$) mice to study AngII-induced AAAs (a few examples from about 200 publications[2,18-22]). This hypercholesterolemic mouse strain is modestly hypercholesterolemic and does not need Western diet to accelerate AngII-induced AAAs.[3] It appears that this mouse strain leads to higher incidence and mortality of AAAs, compared to LDL receptor -/- mice, although plasma cholesterol concentrations in *Apoe*$^{-/-}$ mice fed normal diet are much lower (~ 300 - 400 mg/dl) compared to LDL receptor -/- mice fed Western diet (> 1000 mg/dl),[3] implicating more complex mechanisms of AngII-induced AAAs in *Apoe*$^{-/-}$ mice. Therefore, LDL receptor -/- mice, rather than *Apoe*$^{-/-}$ mice, are optimal to study contributions of hypercholesterolemia and its related mechanisms to AngII-induced AAAs in mice.

The present study provides a guide for researchers who use AngII-induced AAA model: A pre-existing hypercholesterolemic condition accelerates AngII-induced AAAs in LDL receptor -/- mice. Therefore, our standard protocol to feed mice one week of Western diet prior to AngII infusion is optimal.[7] Second, to continuously feed Western diet in LDL receptor -/- mice during AngII infusion is suggested since hypercholesterolemia is important for the progression of AngII-induced AAAs. Dissecting effects of hypercholesterolemia in the human disease is a cost, effort, and time-consuming task, which involves many uncontrolled compound factors. Beyond being a guide how to use this AngII-induced AAA mouse model appropriately, this study, combined with our previous studies, also provides insights into understanding whether and how hypercholesterolemia contributes to AAAs in humans.[3,23,24]

Conclusions

Hypercholesterolemia accelerates both the initiation and progression of AngII-induced AAAs.

Sources of Funding

The authors' research work was supported by the National Institutes of Health under award number R01HL133723 and HL139748. The content in this manuscript is

solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Disclosures

None.

Author Contributions

Conception and design: AD, HSL
Analysis and interpretation: JL, HSL
Data collection: JL, DAH, JJM
Statistical analysis: HSL, OAV
Raw data checking: HS
Writing the article: JL, HS, HSL
Editing the article: AD
Final approval: JL, HS, DAH, JJM, OAV, AD, HSL
Overall responsibility: HSL

REFERENCES

1. Daugherty A, Cassis L. Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice. *Ann NY Acad Sci.* 1999 ;892:108-118.
2. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. *J Clin Invest.* 2000;105:1605-1612.
3. Liu J, Lu H, Howatt DA, Balakrishnan A, Moorleghen JJ, Sorci-Thomas M, Cassis LA, Daugherty A. Associations of apoAI and apoB-containing lipoproteins with AngII-induced abdominal aortic aneurysms in mice. *Arterioscler Thromb Vasc Biol.* 2015;35:1826-1834.
4. Lu H, Howatt DA, Balakrishnan A, Graham MJ, Mullick AE, Daugherty A. Hypercholesterolemia induced by a PCSK9 gain-of-function mutation augments angiotensin II-induced abdominal aortic aneurysms in C57BL/6 mice. *Arterioscler Thromb Vasc Biol.* 2016;36:1753-1757.
5. Deng GG, Martin-McNulty B, Sukovich DA, Freay A, Halks-Miller M, Thinnes T, Loskutoff DJ, Carmeliet P, Dole WP, Wang YX. Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. *Circ Res.* 2003;92:510-517.
6. Uchida HA, Poduri A, Subramanian V, Cassis LA, Daugherty A. Urokinase-type plasminogen activator deficiency in bone marrow-derived cells augments rupture of angiotensin II-induced abdominal aortic aneurysms. *Arterioscler Thromb Vasc Biol.* 2011;31:2845-2852.
7. Lu H, Howatt DA, Balakrishnan A, Moorleghen JJ, Rateri DL, Cassis LA, Daugherty A. Subcutaneous angiotensin II infusion using osmotic pumps induces aortic aneurysms in mice. *JoVE.* 2015;103:e53191.

8. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. *J Clin Invest.* 1994 ;93:1885-1893.
9. Tsukamoto K, Tangirala RK, Chun S, Usher D, Pure E, Rader DJ. Hepatic expression of apolipoprotein E inhibits progression of atherosclerosis without reducing cholesterol levels in LDL receptor-deficient mice. *Mol Ther.* 2000;1:189-194.
10. Bjorklund MM, Hollensen AK, Hagensen MK, Dagnaes-Hansen F, Christoffersen C, Mikkelsen JG, Bentzon JF. Induction of atherosclerosis in mice and hamsters without germline genetic engineering. *Circ Res.* 2014 ;114:1684-1689.
11. Robinet P, Milewicz DM, Cassis LA, Leeper NJ, Lu HS, Smith JD. Consideration of sex differences in design and reporting of experimental arterial pathology studies-Statement From ATVB Council. *Arterioscler Thromb Vasc Biol.* 2018;38:292-303.
12. Henriques T, Zhang X, Yiannikouris FB, Daugherty A, Cassis LA. Androgen increases AT1a receptor expression in abdominal aortas to promote angiotensin II-induced AAAs in apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol.* 2008;28:1251-1256.
13. Sawada H, Chen JZ, Wright BC, Moorleghen JJ, Lu HS, Daugherty A. Ultrasound imaging of the thoracic and abdominal aorta in mice to determine aneurysm dimensions. *J Vis Exp.* 2019;e59013.
14. Daugherty A, Whitman SC. Quantification of atherosclerosis in mice. *Methods Mol Biol.* 2003;209:293-309.
15. Daugherty A, Rateri DL. Development of experimental designs for atherosclerosis studies in mice. *Methods.* 2005;36:129-138.
16. Daugherty A, Tall AR, Daemen MJAP, Falk E, Fisher EA, Garcia-Cardena G, Lusis AJ, Owens AP 3rd, Rosenfeld ME, Virmani R. Recommendation on design, execution, and reporting of animal atherosclerosis studies: A Scientific Statement from the American Heart Association. *Arterioscler Thromb Vasc Biol.* 2017;37:e131-e157.
17. Ference BA, Ginsberg HN, Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J.* 2017;38:2459-2472.
18. Yoshihara T, Shimada K, Fukao K, Sai E, Sato-Okabayashi Y, Matsumori R, Shiozawa T, Alshahi H, Miyazaki T, Tada N, Daida H. Omega 3 polyunsaturated fatty acids suppress the development of aortic aneurysms through the inhibition of macrophage-mediated inflammation. *Circ J.* 2015;79:1470-1478.
19. Umebayashi R , Uchida HA, Kakio Y, Subramanian V, Daugherty A, Wada J. Cilostazol attenuates angiotensin II-induced abdominal aortic aneurysms but not atherosclerosis in apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol.* 2018;38:903-912.
20. Deguchi JO, Huang H, Libby P, Aikawa E, Whittaker P, Sylvan J, Lee RT, Aikawa M. Genetically engineered resistance for MMP collagenases promotes abdominal

aortic aneurysm formation in mice infused with angiotensin II. *Lab Invest.* 2009;89:315-326.
21. Moran CS, Biros E, Krishna SM, Wang Y, Tikellis C, Morton SK, Moxon JV, Cooper ME, Norman PE, Burrell LM, Thomas MC, Golledge J. Resveratrol inhibits growth of experimental abdominal aortic aneurysm associated with upregulation of angiotensin-converting enzyme 2. *Arterioscler Thromb Vasc Biol.* 2017;37:2195-2203.
22. Sawada H, Hao H, Naito Y, Oboshi M, Hirotani S, Mitsuno M, Miyamoto Y, Hirota S, Masuyama T. Aortic iron overload with oxidative stress and inflammation in human and murine abdominal aortic aneurysm. *Arterioscler Thromb Vasc Biol.* 2015;35:1507-1514.
23. Forsdahl SH, Singh K, Solberg S, Jacobsen BK. Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the Tromso Study, 1994-2001. *Circulation.* 2009;119: 2202-2208.
24. Chun KC, Teng KY, Chavez LA, Van Spyk EN, Samadzadeh KM, Carson JG, Lee ES. Risk factors associated with the diagnosis of abdominal aortic aneurysm in patients screened at a regional Veterans Affairs health care system. *Ann Vasc Surg.* 2014;28:87-92.